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Abstract
Reduced Brain-Derived Neurotrophic Factor (BDNF) levels have been described in a number of patho-physiological
conditions, most notably, in Huntington’s disease (HD), a progressive neurodegenerative disorder. Since BDNF is also
produced in blood, we have undertaken the measurement of its peripheral levels in the attempt to identify a possible link
with HD prognosis and/or its progression. Here we evaluated BDNF level in 398 blood samples including 138 controls, 56
preHD, and 204 HD subjects. We found that BDNF protein levels were not reliably different between groups, whether
measured in plasma (52 controls, 26 preHD, 105 HD) or serum (39 controls, 5 preHD, 29 HD). Our experience, and a re-
analysis of the literature highlighted that intra-group variability and methodological aspects affect this measurement,
especially in serum. We also assessed BDNF mRNA levels in blood samples from 47 controls, 25 preHD, and 70 HD subjects,
and found no differences among the groups. We concluded that levels of BDNF in human blood were not informative
(mRNA levels or plasma protein level) nor reliable (serum protein levels) as HD biomarkers. We also wish to warn the
scientific community in interpreting the significance of changes measured in BDNF protein levels in serum from patients
suffering from different conditions.
Citation: Zuccato C, Marullo M, Vitali B, Tarditi A, Mariotti C, et al. (2011) Brain-Derived Neurotrophic Factor in Patients with Huntington’s Disease. PLoS ONE 6(8):
e22966. doi:10.1371/journal.pone.0022966
Editor: Xiao-Jiang Li, Emory University, United States of America
Received May 24, 2011; Accepted July 3, 2011; Published August 12, 2011
Copyright:  2011 Zuccato et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was supported by the NeuroNE Sixth Framework Programme, European Union, LsHM-CT-2004-512039; the Stem-HD Sixth Framework
Programme, European Union, LsHB-CT-2006-037349; and the CHDI Foundation (USA) to EC. Some of this work was undertaken at UCLH/UCL, which received a
proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. ACBL was supported by Gis - Maladies rares
(A04159JS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: elena.cattaneo@unimi.it
. These authors contributed equally to this work.
¤ Current address: Siena Biotech S.P.A., Siena, Italy
Introduction
Reductions in Brain-Derived Neurotrophic Factor (BDNF)
levels have been implicated in various pathological conditions
affecting different organs [1,2,3,4,5]. BDNF has been detected also
in the blood [6,7,8]. Because of its accessibility, interest has been
kindled in the assessment of BDNF protein in blood, with the
primary goal of determining whether its levels correlate to a given
pathology and/or its progression or response to drugs. A summary
of the most critical papers reporting such measurement is
presented in Table S1 (BDNF measurements in human serum)
and S2 (BDNF measurement in human plasma). In particular,
low brain BDNF levels have been described in various
neurodegenerative disorders, most notably, Huntington’s Disease
(HD), a progressive neurodegenerative disorder caused by a CAG
trinucleotide expansion in the gene that encodes huntingtin [9,10].
Reduced level of BDNF protein and mRNA have been found in
HD cells, in brain tissues from HDmice and in human post-mortem
material [10]. A similar reduction in BDNF mRNA level was found
in HD rodent blood [11]. Furthermore, treatment of HD mice with
the MLK inhibitor CEP-1347 led to increase in total BDNF mRNA
in the blood and brain [11,12]. Recently, some of the current authors
(JS, AC) have reported that serum BDNF was significantly lower in
patients with HD than in age-matched healthy subjects [13] and
other authors reported significantly higher levels in patients treated
with riluzole [14]. However, intra-group variability may be
problematic, especially since BDNF protein level is sensitive to a
variety of factors [15,16,17,18]. Here we have undertaken a study
aimed at evaluating BDNF level in the peripheral blood of HD
patients, in order to investigate its robustness as a biological predictor
of HD prognosis and drug efficacy.
Materials and Methods
Study design
Subjects were recruited from the National Neurological Institute
‘‘Carlo Besta’’, Milan (Italy), the National Hospital for Neurology
and Neurosurgery (London UK), the IRCCS Istituto Auxologico
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Italiano, Milan (Italy), and the Henri Mondor Hospital, Cre´teil
(France). In total, samples from three Italian Cohorts (A,B for
serum measurements; C for whole blood detection), one French
Cohort (for detection in plasma) and three UK Cohorts (A, for
plasma detection; B,C for whole blood) were collected and
analyzed (see Table 1 and 2 ).
Ethics statement
All eligible participants received verbal and written information
about the study, and provided signed, informed consent, according
to the Declaration of Helsinki. Department of Neurodegenerative
Disease, UCL Institute of Neurology University College London and
National Hospital for Neurology and Neurosurgery, London: the
study was approved by National Hospital of Neurology and
Neurosurgery & Institute of Neurology Joint Research Ethics
Committee (Central London REC 3). Centre National de re´fe´rence
maladie deHuntington, GHUChenevierMondor, Cre´teil: the study
was approved by the CPP (Comite´ de protection des personnes)
Henri Mondor, Cre´teil, France. National Neurological Institute-
IRCCS ‘‘Carlo Besta’’: the study was approved by the Istituto
Neurologico ‘‘Carlo Besta’’ Institutional Review Board. IRCCS
Istituto Auxologico Italiano, Milano: the study was approved by The
Ethics Committees of IRCCS Istituto Auxologico Italiano ‘‘Comi-
tato Etico dell’IRCCS Istituto Auxologico Italiano di Milano’’.
Patients exclusion/inclusion criteria
Symptomatic HD patients. This group included patients
that were positive on the molecular test for the presence of a
CAG triplet with .35 repeats in the Huntington gene. They also
manifested clinical signs and symptoms of HD. Clinical
assessments of motor signs, disease staging and total functional
capacity (TFC) were determined with the Unified Huntington’s
Disease Rating Scale (UHDRS). The age at onset was
considered the time when clear motor signs and symptoms
were first noticed.
Pre-HD individuals. We enrolled subjects that had more
than 35 CAG triplet repeats in the Huntington gene, with no
clinical symptoms or signs of the disease, and a UHDRS motor
diagnostic confidence score of ,4. For each pre-HD individual,
the estimated probability of onset within the next 5 years was
calculated on the basis of the number of CAG repeats and his/her
present age, according to Langbehn [19].
Control individuals. This group included volunteers with
no neurodegenerative disorders. Patients and controls were
excluded from the study who were ,18 years old and had
known major medical conditions in addition to the primary
genetic disorder.
Blood sampling and processing
For patients and control subjects from Henri Mondor Hospital,
Cre´teil, and from the Neurological Institute-IRCCS ‘‘Carlo Besta’’
in Milan, blood samples were always withdrawn after an overnight
fast. For patients from IRCCS Istituto Auxologico Italiano in
Milan, blood samples were withdrawn after breakfast. From UCL
Institute of Neurology, London, non-fasted samples were with-
drawn.
Table 1. Clinical and genetic characteristics of HD, preHD and healthy patients.
Samples N6 Gender (F/M) Age CAG Size
Serum Italian Cohort A controls 32 20/12 43(28–69) -
preHD 5 3/2 - 42(38–44)
HD 22 8/14 53(32–79) 45(39–51)
Italian Cohort B controls 7 - 39(36–58) -
HD 7 - 53(35–75) 43(41–45)
Plasma French Cohort controls 22 - 55(26–82) -
preHD 4 2/2 39(36–41) 43(42–44)
HD* 40 21/15 44(25–65) 44(40–50)
UK Cohort A controls 30 19/11 47(26–72) -
preHD 22 11/11 38(23–53) 43(40–47)
HD 65 35/30 48(22–80) 45(39–64)
Whole blood UK Cohort B controls 8 4/4 45(28–63) -
preHD 10 7/3 42(27–54) 42(40–44)
earlyHD 11 5/6 48(33–67) 43(40–48)
moderateHD 11 7/4 50(28–63) 49(41–56)
UK Cohort C controls 16 7/9 46(25–68) -
preHD 11 5/6 44(28–56) 42(38–44)
earlyHD 15 10/5 49(33–65) 43(40–49)
moderateHD 9 6/3 65(29–77) 48(41–56)
Italian Cohort C controls 23 13/10 36(21–60) -
preHD 4 3/1 36(28–42) 46(40–47)
HD 24 12/12 47(28–68) 45(41–83)
Italian Cohort A, Istituto Auxologico Italiano, Milano; Italian Cohort B, National Neurological Institute ‘‘Carlo Besta’’ Milan; French Cohort, Henry Mondor Hospital, Creteil;
UK Cohort, National Hospital for Neurological and Neurosurgery.
*sex, age and CAG missing for 4 samples. Age and CAG size are expressed as median values (min-max).
doi:10.1371/journal.pone.0022966.t001
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Plasma
French Cohort. 5 ml of blood were collected in EDTA-treated
tubes between 9:00 and 12:00 a.m. Blood samples were
maintained at room temperature (RT; 20–25uC) until plasma
separation, which was performed up to 4 to 5 hours later. Tubes
were centrifuged for 20 minutes at 30006g in order to separate
plasma from cellular components; plasma samples were stored in
1 ml aliquots at 280uC. Control, HD, and preHD subjects were
recruited on the same day.
UK Cohort A. 5 ml of blood were collected in EDTA-treated
tubes between 2:00 pm and 5:00 pm. Blood samples were
maintained at RT until plasma separation, which was performed
within 2 hours. Blood was transferred to a histopaque tube (A6929
ACCUSPINTM System-HISTOPAQUEH-1077 Sigma Aldrich,
St. Louis, MO, USA) and centrifuged for 10 minutes at 10006g in
order to separate plasma from cellular components; plasma
samples were stored in 1 ml aliquots at 280uC and shipped in
200 ml aliquots.
Serum
Italian Cohort A. 3 ml of blood were collected between 9:00
and 12:00 a.m., after breakfast. Blood samples were maintained at
RT for 1 hour, and serum was separated by centrifugation at RT
for 10 minutes (20006g). Serum samples were stored in 150 ml
aliquots at 280uC.
Italian Cohort B. 3 ml of blood were collected between 9:00
and 12:00 a.m., after an overnight fast. Blood samples were
maintained at RT for 1 hour, and serum was separated by
centrifugation at RT for 10 minutes (20006g). Serum samples
were stored in 150 ml aliquots at 280uC.
RNA
UK Cohort B, C and Italian Cohort C. Whole venous blood
was collected in an evacuated blood collection tube (PAXgeneTM
Blood RNA Tube, BD, Franklin Lakes, NJ, USA) that contained a
stabilizing additive between 2:00 pm and 5:00 pm. The PAX tubes
were left at room temperature for 2 hours as per Qiagen protocol
and then stored at 280uC until RNA extraction.
BDNF ELISA
Plasma and serum samples were assayed for BDNF protein
levels with the BDNF Emax ImmunoAssay System (Promega,
Madison WI, USA). In order to minimize inter-sample variance
resulting from experimental variation, all samples were measured
simultaneously and with BDNF ELISA kits from the same batch.
Internal standards for the BDNF ELISA kit were used as suggested
by [20] and consisted of (a) a standard curve performed in each
experiment to allow BDNF protein quantification, and (b) one
standard sample present on all plates. Plasma and serum aliquots
were thawed on the same day of the experiment at 9:00 a.m.
Plasma was diluted at 1:20 in PBS1X; serum samples were diluted
at 1:300 in PBS1X. Each plasma and serum sample was tested for
BDNF content in three independent ELISA assays. Plasma and
serum dilutions were tested in triplicate on each ELISA plate. A
Synergy HT Multi-Detection Microplate Reader was used to read
absorbance at 450 nm.
RNA extraction
Total RNA was extracted from whole blood with the
PAXgeneTM Blood RNA System Kit (PreAnalytiX, Hombrechti-
kon, CH). Total RNA from brain was isolated from 200–300 mg
of human brain tissue with 2 ml of TRIZOL reagent (Invitrogen,
Carlsbad, CA, USA). The tissue was then homogenised in liquid
nitrogen with a mortar and pestle. To enhance the RNA yield, the
samples were precipitated by adding 2 ml of glycogen solution
(10 mg/ml) in isopropanol, and incubating at 280uC overnight.
Total RNA concentration was measured with a NanoDrop 1000
Spectrophotometer (Thermo Scientific, Waltham, MA, USA). The
RNA quality was verified by electrophoresis of 1 mg from each
sample on an agarose gel. The total RNA was stored in aliquots at
280uC.
Reverse transcription of RNA
250 ng of total RNA was reverse-transcribed to single-stranded
cDNA with Superscript III RNaseH- reverse transcriptase
(Invitrogen, Carlsbad, CA, USA) and random primers in a
volume of 20 ml, according to the manufacturer’s instructions.
Table 2. Medical treatments.
Samples NLPs BDZs SSRIs SSNRIs TCAs Other No drugs
Serum Italian Cohort A HD 6 4 5 1 - 7 4
preHD - - - - - - 5
Italian Cohort B HD 3 2 3 - - 2 4
preHD - - - - - - -
Plasma French Cohort HD 10 6 9 - 5 11 16
preHD - - - - - - 4
UK Cohort A HD 7 1 7 1 - 10 7
preHD - - - - - - -
Blood UK Cohort B HD 8 4 4 1 2 13 3
preHD - - 2 - - 1 7
UK Cohort C HD 3 - 8 1 - 5 8
preHD - - 3 - - 2 7
Italian Cohort C HD 15 7 8 3 1 4 11
preHD - - - - - - 4
NLPs, neuroleptics; BDZ, benzodiazepines; SSRIs, selective serotonin reuptake inhibitors; SSNRIs, selective serotonin-norepinephrine reuptake inhibitors; TCAs, tricyclic
antidepressants.
doi:10.1371/journal.pone.0022966.t002
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Two independent reverse transcription reactions were performed
for every RNA stock. For the analyses of BDNF mRNA isoforms
in whole blood, 2 mg of total RNA was reverse-transcribed to
single stranded cDNA. For the analyses of BDNF mRNA in the
cortex, 1 mg of total RNA was reverse-transcribed to single
stranded cDNA.
Real-time PCR
Three independent PCR analyses were performed for each of
two independent reverse transcription reactions; thus, a total of six
independent measurements were performed for each of the
analysed mRNA. We used an iCycler Thermal Cycler with a
Multicolour Real-time PCR Detection System (Bio-Rad, Hercules,
CA, USA). All reactions were performed in a total volume of 25 ml
that contained 5 ml of cDNA (1:10 dilution of reverse transcribed
samples for BDNF, ROCK1, ANXA1, GAPDH, B2M and ß-
actin amplification or 1:200 dilution of reverse transcribed samples
for EAR amplification), 50 mM KCl, 20 mM Tris-HCI, pH 8.4,
0.2 mM dNTPs, 25 units/ml iTaq DNA polymerase, 3 mM
MgCl2, SYBR Green I with 10 nM fluorescein and stabilisers
(iQTM SYBR Green Supermix-Biorad, Hercules, CA, USA), and
0.3 mM each of forward and reverse primers. The amplification
cycles consisted of an initial denaturing cycle at 95uC for
3 minutes, followed by 45 cycles of 30 s at 95uC, 30 s at 60uC,
and 30 s at 72uC. Fluorescence was quantified during the 60uC
annealing step, and product formation was confirmed with a
melting curve analysis (55uC–94uC).
The BDNF-specific primers were based on the BDNF coding
sequence (GenBank accession number AF411339), as follows:
BDNF 59-TAACGGCGGCAGACAAAAAGA-39; BDNF 59-
GAAGTATTGCTTCAGTTGGCCT-39. The amplification pro-
duct was 101 base pairs (bp) long. The expressed Alu repeat
(EAR)-specific primers were based on the human interspersed Alu
repetitive sequence. The primer sequences were: EAR 59-
GAGGCTGAGGCAGGAGAATCG-39 EAR 59-GTCGCCCA-
GGCTGGAGTG-39. The amplification product was 87 bp long.
The ANXA1 specific primers were set up referring to GenBank
accession number NM_000700.1. The primers sequences were
Fw: 59- GAGCCCCTATCCTACCTTCAAT-39; Rev: 59-GAT-
GGTTGCTTCATCCACACCT-39. The amplification product
was 88 bp long. The ROCK1 specific primers were set up
referring to GenBank accession number NM_005406.2.
The primers sequences were Fw: 59-AGGTTAGGGCGAAAT-
GGTGTAGAA-39; Rev: 59-CCTCTCCTTTATCTTCTTCCA-
AGTC-39. The GAPDH specific primers were set up referring to
GenBank accession number NC_000012.10. The primer sequenc-
es were: GAPDH Fw: 59-AGCTGAACGGGAAGCTCACT-39
GAPDH Rev: 59-AGGTCCACCACTGACACGTTG-39. The
amplification product was 67 bp long. The B2M specific primers
were set up referring to GenBank accession number NC_000
015.8. The primer sequences were: B2M Fw: 59-GGAGAGA-
GAATTGAAAAAGTGGAGC-39; B2M Rev: 59-GGCTGTGA-
CAAAGTCACATGGTT-39. The amplification product was
143 bp long. The ß-actin specific primers were set up referring
to GenBank accession number NC_000007.12. The primer
sequences were: Fw: 59- AGTGTGACGTGGACATCCGCA-39;
Rev: 59- GCCAGGGCAGTGATCTCCTTCT-39. The amplifi-
cation product was 112 bp long.
Qualitative PCR
Semi-quantitative PCRs were performed in a total volume of
50 ml, consisting of 100 ng of cortex cDNA or 200 ng of blood
cDNA, 20 mM Tris-HCl pH 8.4, 50 mM KCl, 1.5 mM MgCl2,
0.2 mM dNTPs, 0.4 mM each of forward and reverse primers, and
2.5 units of Taq polymerase (Invitrogen). The amplification cycles
consisted of an initial denaturing cycle at 94uC for 5 minutes,
followed by 35 cycles (or 40) of 1 minute at 94uC, 45 s at different
temperatures, according to the melting temperature of the
primers, and 45 s at 72uC. The sequences of all primers, their
annealing temperatures, and the lengths of the PCR products are
provided upon request.
Statistical analyses
As BDNF values do not have a normal distribution in both
control and HD populations, the non-parametric Kruskal-Wallis
test followed by Dunn’s Multiple comparison test or Mann-
Whitney two- tailed U-test were used for the statistical analyses,
with significance being set at P,0.05. Median values were chosen
because of the skewed distribution of the data. In the box plots, the
boundary of the box closest to zero indicates the 25th percentile,
the line within the box marks the median, and the boundary of the
box farthest from zero indicates the 75th percentile. When 10 or
more samples were analyzed, whiskers appear above and below
the box to indicate the 90th and 10th percentiles. Unpaired t-test
and Spearman’s rank correlation coefficient were also used.
Results
BDNF protein detection
BDNF in plasma. In a preliminary ELISA assay we noticed
that the time between withdrawal and plasma preparation affected
the detectable BDNF levels in plasma. Plasma prepared 1 hour
after blood withdrawal showed BDNF values of 462.4 ng/ml that
were lower than those prepared at 4 hours (1462.1 ng/ml) and
24 hours (1662.4 ng/ml) after withdrawal (Fig. 1A) (P,0.05
compared to samples processed after 1 hour, unpaired t-test). The
higher than expected BDNF levels measured in these plasma
samples could be due to BDNF release from platelets [7].
To devise a more standardised plasma preparation, and to
ensure a significant number of samples available for testing, we
conducted our first study on plasma samples from the Blood Bank
of the Henry Mondor Hospital in Creteil (French Cohort, see
Table 1). The subjects included 40 with HD, 4 with preHD, and
22 controls. As shown in Fig. 1B, an increase in plasma BDNF
protein level was observed in HD patients at early, moderate and
advanced HD stages, compared to controls (P,0.05 by Kruskal-
Wallis test followed by Dunn’s multiple comparison test Fig. 1B).
Although the median value of BDNF content tended to increase
from the early to moderate or advanced stages, the difference
between these groups was not significant (P.0.05 by Kruskal-
Wallis test followed by Dunn’s multiple comparison test).
Furthermore, we found no correlations between BDNF content
and disease progression measured by TFC and UHDRS scores, or
the CAG-repeat length (P.0.05, Spearman test). Antidepressants
were reported to increase BDNF levels in the serum of depressed
subjects [21]. We found no differences in BDNF content between
antidepressant-free and antidepressant-treated HD subjects
(P.0.05, Mann-Whitney two-tailed U-test).
To evaluate further whether increased levels of blood BDNF
protein were consistently detected in human HD blood, we
increased the number of subjects tested. A new batch of plasma
samples was obtained from University College London (UCL, UK
Cohort A, Table 1), including 30 controls, 22 preHD, and 65
HD. According to UCL internal procedures, plasma preparations
for the UK Cohort A were performed differently than those
prepared for the French Cohort. Blood samples were collected
after breakfast (and not after an overnight fast as for the French
Cohort) and plasma samples were prepared within 2 hours of
BDNF in Blood of HD Patients
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blood withdrawal (compared to 4 hours after for the French
Cohort). Fig. 1C shows that the median BDNF level in plasma
from control subjects of the UK Cohort A was 0.8 ng/ml
compared to the 3.8 ng/ml measured in plasma samples from
controls of the French Cohort (Fig. 1B). This is likely to be due to
differences in samples preparation. The lower than expected
BDNF levels found in the UK cohort could be due to lower
platelet activation and minimal BDNF release. Therefore, we
analysed the samples from these two cohorts separately. We found
no difference in BDNF levels between the HD and control
populations (P.0.05 by Kruskal-Wallis test followed by Dunn’s
multiple comparison test; Fig. 1C). This contrasted with the
results from the French Cohort, which indicated that the BDNF
protein content was significantly higher in HD patients compared
to controls (Fig. 1B). The most likely explanation for these
different results was the different protocols used in the plasma
preparation and the many variables related to the patients
recruitment. Further, we found that BDNF protein content in
the UK Cohort A did not correlate with disease progression.
Additionally, we found no difference in BDNF content between
antidepressant-free and anti-depressant treated HD subjects
(P.0.05, Mann-Whitney two-tailed U-test). Our analyses revealed
also that BDNF protein in 22 preHD subjects was lower than in
early HD (P,0.05 by Kruskal-Wallis test followed by Dunn’s
multiple comparison test; Fig. 1C). We calculated the 95%
probability that preHD subjects would exhibit onset symptoms
within 5 years (based on the number of CAG repeats) [19]. We
found a tendency of BDNF to decrease in subjects predicted to be
near disease onset, but the correlation was not significant (P.0.05,
Spearman test). Five out of the 8 subjects close to onset (5-year
probability .0.3) had BDNF levels in the lower range while the
other 3 subjects, which exhibited BDNF levels higher or similar to
controls, were predicted to be further away from onset (Figure
S1).
In conclusion, control and HD subjects from two independent
Cohorts showed completely different BDNF levels. This is likely to
be due to differences in samples preparations or intra-group
variability, because BDNF levels are sensitive to a variety of factors
(for example age and sex) [15,16,17,22]. However, no sex- and
age-related changes in BDNF blood concentration were found
both in control and HD populations.
BDNF in serum. A previous report from some of the authors
(AC and JS) of this paper indicated a decrease in BDNF level in
human HD blood [13]. We have asked this group to join our study
and to provide us with their old/new samples (control and HD)
and/or re-perform this measurement. A first cohort (Italian
Cohort A, see Table 1) including 32 controls, 5 preHD, and 22
HD patients was recruited by AC Unit at Istituto Auxologico in
Milan and BDNF content was first evaluated in July 2009 in a
subgroup including 29 control and 19 HD samples. A not
significant decreasing tendency in serum BDNF content was
observed in HD subjects compared to controls (median BDNF
level in serum from controls was 10.7 ng/ml compared to 5.9 ng/
ml in HD subjects; P.0.05 compared to controls, Mann-Whitney
Test). In October 2009 a second evaluation on the same samples
(new aliquots of serum), added of 1 control, 4 preHD and 3 HD,
was performed by other authors on this paper (BV and CZ).
Again, serum BDNF level was similar in control and HD patients
(P.0.05, Kruskal-Wallis test followed by Dunn’s multiple
comparison test) (Fig. 2A). Because the variability in serum
BDNF content was high in both the control and HD populations,
a replicate of this experiment was performed 6 days later with the
same ELISA kit and reagents. This experiment confirmed the high
variability in serum BDNF in both groups, and the absence of a
Figure 1. BDNF protein in human plasma measured by ELISA.
(A) BDNF content in plasma samples from 3 control subjects. After blood
withdrawal, samples remained at RT for 1, 4, and 24 hours before the
plasma was isolated (p,0.05 compared to sample processed after
1 hour, unpaired t-test). (B) BDNF protein levels in plasma samples from
the French Cohort, prepared 4 hours after blood withdrawal. Control and
HD subjects exhibited a large variability in plasma BDNF levels. Values
inside the boxes are the medians for the group. P,0.05, controls vs early
HD, P,0.05 controls vs moderate HD and P,0.05 controls vs advanced
HD, according to Kruskal-Wallis test followed by Dunn’s multiple
comparison test (C) BDNF protein contents in plasma samples from UK
Cohort A, prepared 2 hours after blood withdrawal. BDNF protein in
preHD was significantly lower than that in early HD, P,0.05 according to
Kruskal-Wallis test followed by Dunn’s multiple comparison test.
doi:10.1371/journal.pone.0022966.g001
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significant difference in serum BDNF levels between control and
HD patients (P.0.05) according to Kruskal-Wallis test followed by
Dunn’s multiple comparison test)(Fig. 2B). We also observed that
16 out of 30 controls and 20 out of 22 patients with HD showed
significant differences between the first and second measurements
(.15%). These results suggested that caution should be taken
when interpreting data on BDNF serum, because inter-assay
variation is very high despite our best efforts at methodological
consistency (Text S1). In parallel, we tested a small group of
serum samples (7 from controls and 7 from HD patients, Italian
Cohort B, see Table 1) obtained by CM and SD at the National
Neurological Institute ‘‘Carlo Besta’’ in Milan. Again, no
differences in the BDNF content were observed between control
and HD subjects (P.0.05, Mann-Whitney Test) (Fig. 2C).
To try to limit inter-assay variations in the BDNF analyses on
serum we have organized our assay in order to test all serum
samples from Italian Cohorts A and B (new serum aliquots that
were never thawed before) on the same day and BV and JS have
worked in parallel with the same sample dilutions, ELISA assays,
reagents, solutions, and bench. This experiment was performed in
January 2010. As shown in Fig. 2D, both operators found no
significant differences in serum BDNF protein content between
control, pre-HD and HD subjects (JS: P.0.05; BV: P.0.05,
Kruskal-Wallis test followed by Dunn’s multiple comparison test).
Inter-assay variation still remained very high (Text S1).
Moreover, the absolute amounts of BDNF content in serum were
lower in this measurement than those found in the previous
measurement (Fig. 2A), suggesting that the storage conditions
(280uC) affected BDNF stability in serum samples. These data
suggested that measurement of BDNF protein in human serum
should be interpreted with extreme caution. Further, in contrast to
previous findings [13], we did not detected any difference in serum
BDNF content between control and HD patients.
BDNF mRNA in control and HD patients
There is a remarkable reduction in brain BDNF mRNA levels
in patients with HD as judged from analyses of post-mortem tissue
[23]. Studies in mouse models of HD indicated that blood BDNF
mRNA also gradually diminishes with disease progression [11,12].
Due to our failure to detect reliably the BDNF protein in human
Figure 2. BDNF protein measured in human serum. (A) BDNF protein in serum from controls and subjects with preHD or HD in Italian Cohort A.
(B) The samples in A were tested 1 week later. (C) BDNF levels in control and HD serum samples from the Italian Cohort B. (D) Serum BDNF content
determined 3 months later. The following samples were tested: (i) thirty-nine controls, including 32 from Italian Cohort A and 7 from Italian Cohort B.
From Italian Cohort A 30 had been tested previously and 2 were new samples. All those from Italian Cohort B had been tested previously; (ii) five with
preHD from Italian Cohort A, including 4 samples that were previously tested and one new sample; (iii) twenty-seven with HD, including 20 out of 22
samples from Italian Cohort A and 7 samples from Italian Cohort B. Duplicate experiments were performed in parallel by two different operators
(operator A, JS; operator B, BV). Operator B: BDNF protein content was undetectable in 1 preHD sample and in 3 HD samples which were excluded
from data analyses.
doi:10.1371/journal.pone.0022966.g002
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blood, we decided to measure BDNF mRNA in the blood of
patients with HD and controls. In our initial RT-qPCR assays, we
measured BDNF mRNA levels in the blood of 8 controls, 10
preHD, and 22 HD subjects (UK Cohort B, see Table 1). BDNF
mRNA levels showed a tendency to decrease in HD patients with
respect to controls and preHD samples after normalisation to the
mRNA of the housekeeping gene, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), although this difference was not
statistically significant (P.0.05 by Kruskal-Wallis test followed
by Dunn’s multiple comparison test; Fig. 3A). Similarly, when
BDNF mRNA from the same samples was normalised to ß2-
microglobulin, a component of major histocompatability class I
molecules present in all nucleated cells, we found that BDNF
mRNA levels were not significantly different among control,
Figure 3. Analyses of BDNF mRNA in whole blood from control and HD subjects. (A) Samples from UK Cohort B: BDNF mRNA levels
normalised with GAPDH mRNA. (B) Samples from UK Cohort B: BDNF mRNA levels normalised with ß2-microglobulin (B2M) mRNA. (C) BDNF mRNA
content in the same samples shown in (A) was normalised with EAR. (D) Samples from UK Cohort C: BDNF mRNA was normalised with EAR. (E)
Samples from Italian Cohort C: BDNF mRNA was normalised with EAR.
doi:10.1371/journal.pone.0022966.g003
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preHD, and HD (P.0.05 by Kruskal-Wallis test followed by
Dunn’s multiple comparison test) (Fig. 3B). Since we have
previously demonstrated the possibility of erroneous quantification
of a target gene in human blood when a conventional
normalization strategy based on a single control gene is used
[24], we decided to re-analyse the samples still available by using a
more accurate strategy for mRNA normalisation in RT-qPCR
based on amplification of the expressed Alu repeat (EAR) [24].
When BDNF mRNA content in blood was normalised over EAR,
we found no differences among control (n = 6), preHD (n= 10),
and HD subjects (n = 21) (P.0.05 by Kruskal-Wallis test followed
by Dunn’s multiple comparison test) (Fig. 3C). Similar results
were obtained on two additional sets of samples (16 control, 11
preHD, and 24 HD samples) from UK Cohort C (P.0.05 by
Kruskal-Wallis test followed by Dunn’s multiple comparison test)
(Fig. 3D), and 23 control, 4 preHD, and 24 HD samples from
Italian Cohort C (Fig. 3E) (P.0.05 by Kruskal-Wallis test
followed by Dunn’s multiple comparison test). These analyses
confirmed that the blood level of BDNF mRNA is similar in
control and HD patients.
Validation of previously identified transcriptomic
biomarkers
A previous microarray study identified a large number of
significantly altered mRNAs in HD blood, from which 12 genes
were selected to discriminate between controls and HD patients
[25]. Some of the HD-related changes in the expression of these
12 genes were confirmed in one independent study [26], but not in
a second one [27]. Here we analysed the expression of 2 of the
putative marker genes in a selection of samples from the Italian
Cohort C that were previously tested for BDNF mRNA content.
We focused on the annexin A1 (ANXA1) and rho-associated
protein kinase-1 (ROCK1) genes, because their expression was
upregulated in HD blood and was sensitive to pharmacological
treatment [25,26]. Our RT-qPCR experiments indicated that
ANXA1 and ROCK1 mRNA levels were similar in control and
HD patients (Fig. 4A–B). Two different normalization factors
were used, ß-actin, as reported in the original article [25]
(ANXA1: P.0.05 controls vs HD; ROCK1: P.0.05 controls vs
HD, Mann-Whitney test) and EAR [24] (ANXA1: P.0.05
controls vs HD; ROCK1: P.0.05 controls vs HD, Mann-Whitney
test), with similar results although normalization over ß-actin
caused increased variability. Our results were consistent with
previous findings from Runne et al., [27], who used a larger
number of cases and the same qPCR primer pairs for the selected
targets, but also saw no differential expression in ANXA1 and
ROCK1 between preHD and control samples. Our data confirm
that transcriptomic analyses of these individual genes may not be
suited for tracking HD onset and progression in human blood and
that a reliable normalisation procedure, such as EAR, is necessary.
Discussion
This multicentre study included the largest number of HD
subjects, to date, that have been tested for peripheral BDNF
mRNA and protein expression, and represents the most
comprehensive experimental analysis of BDNF in peripheral
Figure 4. mRNA levels of other HD-related genes in control and HD patients. Samples are from Italian Cohort C. Blood mRNA levels of (A)
ANXA1 and (B) ROCK1 were measured with two different normalisation strategies (ß-actin mRNA levels (ß-ACT), according to [25], and EAR levels,
according to [24].
doi:10.1371/journal.pone.0022966.g004
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human blood. We show that measuring BDNF in the blood of
patients with HD was not informative of disease onset or
progression. Moreover, we have demonstrated that many issues
concerning BDNF protein detection in blood (in particular in
serum) may make reliable measurements difficult. This is true for
HD, but could be extended to other diseases and to all assays in
which serum and plasma BDNF levels have been measured. We
also showed that, with the appropriate normalisation procedures
[24], the evaluation of BDNF mRNA revealed no differences
between control and HD subjects. In spite of this, we propose
pPCR against EAR [24] as a precise and reliable strategy to detect
the level of BDNF mRNA in total blood as well as the level of
other mRNAs.
The measure of circulating BDNF protein
In this study, we analyzed samples from a total of 91 controls,
31 preHD, and 134 HD subjects. We found that the detection of
BDNF protein in human blood samples (plasma and, in particular,
serum) is extremely complex. In particular, variability in serum is
still prohibitive for consideration as a routine clinical tool, and
caution should be exercised when undertaking research studies of
BDNF in such a compartment or in plasma from pre-existing
banks. First, in our study, different results were obtained when
BDNF plasma levels were measured in different cohorts. Second,
intra-group variability can be a major problem especially since
BDNF levels are affected by a number of individual factors [22].
Third, several methodological aspects related to blood collection,
sample storage and BDNF protein detection may contribute to the
variability of its measurement in blood. While considering this, no
differences in BDNF protein content were found between control
and HD patients (in both plasma and serum).
Critical aspects to consider when approaching BDNF
protein detection in plasma samples. We found that sample
collection and preparation may influence the level of BDNF
protein measured in plasma. Particularly, we found that the time
spent on the bench at RT before plasma preparation affects BDNF
content in plasma (Fig. 1A). Thus, more robust and standardised
procedures are required for plasma preparation. BDNF was
enough stable when plasma was stored at280uC, even after 1 year
(data not shown). This is due to the presence of EDTA in blood
collection tubes, which reduces the activity of proteases, thus
increasing BDNF protein stability. Although proteases are not
completely inactivated in plasma samples, our studies and previous
studies demonstrate that plasma is intrinsically more stable than
serum and therefore, more useful for protein analyses in biomarker
studies [28]. Plasma banks might be a suitable method of storing
plasma samples for future BDNF protein analyses. However, if the
disease of interest is a rare genetic disease and only small cohorts of
patients are available, small variations in the protocols used for
different blood banks may introduce issues related to plasma
sample preparation that affect BDNF measure. In fact, we show
here that plasma samples of control and HD subjects from two
independent Cohorts showed different BDNF levels (Fig. 1B and
Fig. 1C). The effort conducted within the EURO-HD network
(http://www.euro-hd.net/html/network) in coordinating Clinical
Centres within Europe is a very welcome and worthwhile strategy
as it aims at the application of standardised protocols in response
to criteria identified by specialists of tissue banking and also
encourages sample deposition in a single bank (for HD studies:
BioRep s.r.l. in Milano, http://www.biorep.com). This effort is
sustained also by the fact that BDNF ELISA works well on plasma
samples (Text S1).
Testing BDNF protein in serum samples: issues that
remain to be resolved. Compared to our findings on BDNF in
plasma, we noticed that BDNF appears to be less stable in serum
samples prepared following standardised protocols (see Material
and Methods) and stored at 280uC. The aspect of protein
instability is serum is well known to enzymologists and biochemists
[29,30]. Proteolytic enzymes in the clotting cascade may greatly,
and randomly, affect the level of a given protein in serum samples.
The activity of proteolytic enzymes may continue also with serum
storage, causing sample variability and instability by sequential
protein degradation. We have found that BDNF is unstable in
frozen samples stored at 280uC as previously raised by other
authors who showed that serum BDNF is rapidly degraded with
storage at 220uC [20]. Moreover, the collection of blood in tubes
containing protease inhibitors has little effect on serum protein
preservation [31]. Instability of BDNF protein in serum samples
clearly emerges from the high inter-assay variation observed in our
study also when the same samples have been tested after one week.
This is not due to the ELISA assay itself that has been extensively
validated in cells, brain tissue and plasma samples [22,23,32].
Based on these considerations, one could think to analyse serum
samples immediately after preparation. However, if the disease
under investigation is rare, it will be very difficult to recruit a
number of patients large enough for statistical analyses. In
addition, we found that inter-assay variation still remains high
when the same serum (but not plasma) samples were analysed in
parallel, on the same day, with the same BDNF ELISA kit and
solutions, by two different operators (JS and BV) (Fig. 2D). This
result is difficult to interpret. The only possible explanation at this
stage is that serum samples may be subjected to uncontrolled
biological (and technical) variations. We suggest that protein
stability in serum samples still remain a complicated and unsolved
issue that renders serum samples inappropriate for the detection of
BDNF (and likely also other proteins) in biomarker studies.
Data about BDNF in blood need to be critically re-
interpreted. Our study suggests also that changes in serum and
plasma samples previously reported to be associated with several
disorders might be considered with cautions. By using the
PubMED search engine with the keywords ‘‘BDNF and human
and serum’’ and ‘‘BDNF and human and plasma’’ we analysed the
literature published between 2003 and May 1, 2011 on BDNF in
blood. 351 articles emerged from the first search while 288 for the
second, some of which could be overlapping. We have selected 30
papers reporting BDNF measurement in human serum and 20
papers in human plasma that contained enough methodological
aspects for a critical analysis (Table S1 and Table S2). Even
among these cases there are reports in which BDNF protein
concentration were described with limited details. BDNF
measured in serum and plasma was variable under different
pathological conditions, but also among control groups. Serum
BDNF content varied from approximately 0.143 to 80 ng/ml, and
plasma BDNF content varied from 10 to 10000 pg/ml. Such a
high variability can be due to different criteria for subject selection,
sample collections and methodological aspects that can seriously
affect BDNF detection in blood. Criteria for patient selection are
not always available in published papers. In addition, most studies
have not indicated whether measurements were made under
fasting or fed conditions, as it is also known that diet can influence
BDNF levels [22]. Most papers do not sufficiently describe the way
blood was collected. Lommatzsch et al., (2005) have shown that
different types of blood collection tubes (EDTA or heparin-treated)
can influence the BDNF content detected in plasma [17]. Many
papers do not contain information on the time and conditions of
blood storage that strongly influence the amount of BDNF
detected in plasma (see Fig. 1A). Temperatures and time of
storage of plasma and serum samples vary among studies, thus
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affecting the absolute amount of BDNF detected. We and others
have found that this is true especially for serum samples [18,20].
Different ELISA assay kits have been used with different range of
sensitivity, thus contributing to introduce variability. However, the
two most used ELISA kits (from Promega and R&D Systems)
efficiently detect BDNF. Underestimated methodological aspects
can affect data interpretation and make it difficult to reach any
strong conclusion about blood BDNF protein content in different
pathological conditions.
The HD mutation did not affect BDNF mRNA in human
peripheral blood
A large number of in vitro and in vivo studies have shown that
BDNF mRNA is consistently reduced in brain tissues from HD
transgenic mice and patients [10,22]. In addition, blood BDNF
mRNA levels correlated with brain BDNF levels and disease
progression in HD mice [11,12]. Importantly, a standardised,
accurate and fast assay is available to quantitatively evaluate
BDNF mRNA in human blood samples [24]. These studies
initiated our investigation of the levels of BDNF mRNA in blood.
Our analyses of samples from 47 control, 25 preHD, and 70
HD subjects indicated that, in contrast to findings in HD mouse
models, BDNF gene transcription was not affected in the
peripheral blood of HD patients. This apparent absence of BDNF
modulation in blood may arise because the transcriptional
regulatory mechanisms are different in human blood and human
brain. The human BDNF gene is characterised by very complex
regulation as it contains nine different promoters that act
independently to modulate the transcription of BDNF mRNA in
a stimulus- and time- specific manner [33]. We previously
demonstrated that transcription from the BDNF promoters II,
IV, and VI was reduced in the brains of HD animal models and in
human postmortem brain tissue [10]. In human blood, most of the
BDNF is produced from mRNA isoform IX, with some very
moderate involvement of mRNA I and IV (the latter being
detectable only at very high PCR amplification cycles; Figure S1)
while others, including those implicated in brain and affected by
the HD mutation appeared to be silent (such as mRNA isoform II;
Figure S1). These differences in BDNF isoforms expression
between blood and brain may account for the differences observed
in the effects of the HD mutation on BDNF gene transcription in
these two compartments.
Furthermore, microarray studies on blood samples from healthy
subjects have shown intra-individual variation in the expression of
several genes due to differences in the relative proportions of
specific blood cell subsets, gender, age, and the time of day at
which the blood was sampled [34]. These factors may also
influence the levels of BDNF mRNA in blood. Consistently, it was
not surprising that the levels of previously identified serum mRNA
markers (ROCK1 and ANXA1) were unaffected by HD in our
cohort of samples and in previous studies [25,27].
Conclusion
Although BDNF loss in the HD brain is implicated in the
disease process [10], this study indicates that the level of BDNF in
human blood is not informative (mRNA levels and plasma protein
level) or reliable (protein levels in serum) as a biomarker for
predicting HD onset or progression.
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